{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:03:16Z","timestamp":1784599396117,"version":"3.55.0"},"reference-count":18,"publisher":"ARAN Ediciones","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.hipert.2024.10.004","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T07:32:21Z","timestamp":1733383941000},"page":"67-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world efficacy and safety of baroreceptor activation therapy in a series of patients with refractory arterial hypertension"],"prefix":"10.20960","volume":"42","author":[{"given":"A.","family":"Bustos-Merlo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rico-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ja\u00e9n-\u00c1guila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"L\u00f3pez-Espada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.I.","family":"Rodr\u00edguez-Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Mediavilla-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2024.10.004_bib0095","series-title":"Utilidad de la monitorizaci\u00f3n ambulatoria de la presi\u00f3n arterial en fenotipos cl\u00ednicos espec\u00edficos","first-page":"7","article-title":"Fundamentos del uso de la monitorizaci\u00f3n ambulatoria de la presi\u00f3n arterial y dispositivos habituales de MAPA utilizados en la pr\u00e1ctica cl\u00ednica","author":"Mart\u00edn","year":"2023"},{"key":"10.1016\/j.hipert.2024.10.004_bib0100","doi-asserted-by":"crossref","DOI":"10.1080\/08037051.2023.2185457","article-title":"What is resistant arterial hypertension?","volume":"32","author":"Shalaeva","year":"2023","journal-title":"Blood Press"},{"key":"10.1016\/j.hipert.2024.10.004_bib0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/HJH.0000000000003621","volume":"42","year":"2024","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2024.10.004_bib0110","first-page":"130","article-title":"Est\u00e1ndares SEA 2022 para el control global del riesgo cardiovascular","volume":"34","author":"Mostaza","year":"2022","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.hipert.2024.10.004_bib0115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11906-022-01185-6","article-title":"An update on refractory hypertension","volume":"24","author":"Matanes","year":"2022","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.hipert.2024.10.004_bib0120","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.hipert.2019.03.001","article-title":"La terapia de activaci\u00f3n de barorreceptores, un paso m\u00e1s en el tratamiento de la hipertensi\u00f3n arterial resistente y la insuficiencia cardiaca","volume":"36","author":"Ja\u00e9n-Aguila","year":"2019","journal-title":"Hipertens Riesgo Vasc"},{"key":"10.1016\/j.hipert.2024.10.004_bib0125","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/s41440-024-01704-9","article-title":"Effects of acute carotid baroreceptor stimulation on sympathetic nerve traffic in resistant and uncontrolled hypertension: a systematic review and meta-analysis","volume":"47","author":"Biffi","year":"2024","journal-title":"Hypertens Res"},{"key":"10.1016\/j.hipert.2024.10.004_bib0130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension","volume":"58","author":"Bisognano","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hipert.2024.10.004_bib0135","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jash.2012.04.004","article-title":"Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial","volume":"6","author":"Hoppe","year":"2012","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.hipert.2024.10.004_bib0140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00392-019-01536-5","article-title":"Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system","volume":"109","author":"Wallbach","year":"2020","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.hipert.2024.10.004_bib0145","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jchf.2015.02.006","article-title":"Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction","volume":"3","author":"Abraham","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hipert.2024.10.004_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2020.05.015","article-title":"Baroreflex activation therapy in patients with heart failure with reduced ejection fraction","volume":"76","author":"Zile","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hipert.2024.10.004_bib0155","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/ejhf.3232","article-title":"Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: long-term outcomes","volume":"26","author":"Zile","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hipert.2024.10.004_bib0160","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.recesp.2021.11.027","article-title":"Gu\u00eda ESC 2021 sobre el diagn\u00f3stico y tratamiento de la insuficiencia cardiaca aguda y cr\u00f3nica","volume":"75","author":"McDonagh","year":"2022","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.hipert.2024.10.004_bib0165","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/ehf2.14473","article-title":"Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: systematic review","volume":"10","author":"Molina-Linde","year":"2023","journal-title":"ESC Heart Fail [Internet]"},{"key":"10.1016\/j.hipert.2024.10.004_bib0170","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/HJH.0000000000000071","article-title":"Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings","volume":"32","author":"Borisenko","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.hipert.2024.10.004_bib0175","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10286-020-00670-9","article-title":"Baroreflex activation therapy reduces frequency and duration of hypertension-related hospitalizations in patients with resistant hypertension","volume":"30","author":"Halbach","year":"2020","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.hipert.2024.10.004_bib0180","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.recesp.2023.09.013","article-title":"Activaci\u00f3n barorrefleja en pacientes con insuficiencia cardiaca y fracci\u00f3n de eyecci\u00f3n reducida","volume":"77","author":"Cordero Pereda","year":"2023","journal-title":"Rev Esp Cardiol"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183724001120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183724001120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:43Z","timestamp":1784596543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1889183724001120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1889183724001120"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2024.10.004","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy and safety of baroreceptor activation therapy in a series of patients with refractory arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2024.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SEH-LELHA. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}